University of North Carolina, Chapel Hill, NC
Duke University, Durham, NC
Graduate Certificate, Project Management
Georgetown University, Washington, DC
Mary Beth Ritchey, PhD, is the Director of Epidemiology, Medical Devices and Real-World Evidence at RTI-HS. In her role at RTI, Dr. Ritchey is responsible for the scientific, technical, and logistic aspects of projects including postmarketing noninterventional safety and effectiveness studies, analyses of the regulatory landscape for novel therapeutics and rare diseases, and consultation on timing, design, and methodological aspects of real-world studies for medical devices and other therapeutic products. She obtained her Masters and PhD in Epidemiology from the UNC Gillings School of Global Public Heath, and obtained a BS in Nursing from UNC and a BS in Chemistry from Duke University. She holds an adjunct faculty appointment in the Center for Pharmacoepidemiology and Treatment Science at Rutgers University.
Before joining RTI-HS, Dr. Ritchey worked in government and industry. At the Center for Devices and Radiologic Health (CDRH) at the Food and Drug Administration (FDA), she served as Associate Director for Postmarket Surveillance Studies in the Division of Epidemiology. At the FDA, she managed and oversaw the Postmarket Surveillance Studies (21 CFR 822) and literature review programs and was involved in the Medical Device Epidemiology Network and FDA Sentinel Initiative. At Merck, she developed comparative data strategies through tools, collaborations, and establishing a continuous learning organization for comparative effectiveness research (CER) in the Comparative and Outcomes Evidence group. In the global safety group at Procter & Gamble, she provided epidemiologic support across the therapeutic and consumer goods portfolio and enhancing the company’s signal management and risk management programs to include interpretation and synthesis across spontaneous adverse events and other safety data sources. Dr. Ritchey has experience with database analyses, literature reviews, utilization and safety surveillance of therapeutic products, registry implementation and governance, and practical application of advanced research methods.
Dr. Ritchey is an active member in the International Society of Pharmacoepidemiology (ISPE), having served on the Scientific Program Committee since 2010 (chair, 2016), functioned as pre-conference course faculty since 2011, and participated within multiple committees and significant interest groups.